MedPath

Effects of Electrical Nervous Stimulation Transcutaneous in Hypertensive Patients

Not Applicable
Not yet recruiting
Conditions
Hypertension
Hypertension,Essential
Interventions
Other: TENS - Plus cervical stimulation group
Other: TENS - Renal stimulation group
Other: TENS - Cervical stimulation group
Registration Number
NCT06025643
Lead Sponsor
Federal University of Health Science of Porto Alegre
Brief Summary

Systemic arterial hypertension is a disease characterized by high blood pressure levels. It has a high prevalence, is a precursor of cardiovascular diseases, resulting in high costs to the health system and increased mortality. Transcutaneous electrical nerve stimulation (TENS) is a low-frequency pulsed electrical current widely used for analgesia. Recently, it has been proposed as a non-pharmacological strategy for blood pressure control. The aim of this study is to verify the effect of low-frequency TENS when applied in different anatomical sites on blood pressure, autonomic control and endothelial function in hypertensive patients.

Detailed Description

Systemic arterial hypertension is a disease characterized by high blood pressure levels. It has a high prevalence, is a precursor of cardiovascular diseases, resulting in high costs to the health system and increased mortality. Transcutaneous electrical nerve stimulation (TENS) is a low-frequency pulsed electrical current widely used for analgesia. Recently, it has been proposed as a non-pharmacological strategy for blood pressure control. The aim of this study is to verify the effect of low-frequency TENS when applied in different anatomical sites on blood pressure, autonomic control and endothelial function in hypertensive patients. For this, patients will be randomized into 4 groups: group 1 (cervical stimulation), group 2 (plus cervical stimulation ), group 3 (renal stimulation), group 4 (control). Group 1 will receive TENS in the cervical paravertebral region; group 2 will receive stimulation in the cervical paravertebral region, ear lobe, wrist and ankle. Group 3 will have the anatomical region of the kidneys stimulated. Group 4 will not receive any intervention. All the treated patients will receive 30 minutes of stimulation per session, regardless of group allocation. Ten applications will be carried out over the course of a month.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Diagnosis of systemic arterial hypertension: systolic blood pressure (SBP) ≥ 130 mmHg and diastolic blood pressure (DBP) ≥ 80 mmHg diagnosed by ambulatory blood pressure monitoring (ABPM).
Exclusion Criteria
  • Congestive heart failure
  • Patients with a cardiac pacemaker
  • Previous heart surgery
  • Patients with serum creatinine >2.5 mg/dL
  • Change in drug therapy in the two months prior to starting the study
  • Active smoking

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Plus cervical stimulation groupTENS - Plus cervical stimulation groupTENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
Renal stimulation groupTENS - Renal stimulation groupTENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
Cervical stimulation groupTENS - Cervical stimulation groupTENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
Primary Outcome Measures
NameTimeMethod
Systolic blood pressureBaseline and after 4 weeks

Systolic blood pressure assessed by ambulatory blood pressure monitoring (ABPM)

Diastolic blood pressureBaseline and after 4 weeks

Systolic blood pressure assessed by ambulatory blood pressure monitoring (ABPM)

Secondary Outcome Measures
NameTimeMethod
Autonomic controlBaseline and after 4 weeks

Autonomic control assessed by analysis of heart rate variability by frequency meter

© Copyright 2025. All Rights Reserved by MedPath